Shandong Provincial Hospital, Affiliated to Shandong First Medical University
Jinan, Shandong, 250000, China
NCT Number: NCT07537933
The goal of this clinical trial is to learn if immediate intra-arterial tirofiban after complete recanalization can improve recovery in adults with acute ischemic stroke caused by anterior circulation large-vessel occlusion. It will also learn about the safety of this treatment. The main questions it aims to answer are:
Does immediate intra-arterial tirofiban after complete recanalization increase the number of participants with good functional outcome at 90 days? Does this treatment increase the risk of symptomatic intracranial hemorrhage or other important bleeding events?
Researchers will compare immediate intra-arterial tirofiban with no intra-arterial tirofiban after complete recanalization to see if tirofiban improves recovery and is safe.
Participants will:
Be enrolled after mechanical thrombectomy achieves complete recanalization Be randomly assigned to receive intra-arterial tirofiban or no intra-arterial tirofiban Receive follow-up assessments during hospitalization and at 90 days
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 3
Jinan, Shandong, 250000, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Age ≥18 years; Last known well to arterial puncture within 0 to 24 hours; Preoperative imaging confirms anterior circulation large-vessel occlusion, including intracranial internal carotid artery occlusion or middle cerebral artery M1 or dominant M2 occlusion; Baseline National Institutes of Health Stroke Scale (NIHSS) score 6 to 25; Baseline Alberta Stroke Program Early CT Score (ASPECTS) ≥6 on CT or DWI; Pre-stroke modified Rankin Scale (mRS) score ≤1; eTICI 2c to 3 complete recanalization achieved after mechanical thrombectomy, or spontaneous recanalization to eTICI 2c to 3 confirmed intraoperatively without further thrombectomy; Embolic occlusion with no residual fixed stenosis in the target vessel after thrombectomy; Written informed consent provided by the participant or legally authorized representative.
Exclusion criteria
Pregnancy or breastfeeding; Active bleeding within the previous month or known severe bleeding tendency; Major underlying disease with life expectancy <6 months, or inability in the investigator's judgment to complete follow-up; Participation in another interventional clinical trial; Use of oral anticoagulants within 48 hours before symptom onset with INR >1.7, or recent use of direct oral anticoagulants not meeting institutional cessation or testing requirements; Platelet count <50 × 10^9/L; Blood glucose <2.8 mmol/L or >22.2 mmol/L that cannot be corrected promptly Severe renal insufficiency, defined as eGFR <30 mL/min/1.73 m² or serum creatinine >2.5 mg/dL; Uncontrolled blood pressure, defined as systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg despite treatment; Imaging evidence of intracranial hemorrhage, or presence of an intracranial aneurysm, arteriovenous malformation, brain tumor, or other lesion associated with high bleeding risk; Bilateral acute cerebral infarction or multiple intracranial arterial occlusions Intraoperative vessel rupture, dissection, contrast extravasation, or other severe complications requiring a change in the standard anticoagulation strategy; Need for balloon angioplasty, permanent stent placement, or planned initiation of antiplatelet or anticoagulation therapy within 24 hours after the procedure; More than 3 thrombectomy passes or puncture-to-recanalization time >90 minutes; Use of an intraoperative intravenous heparin bolus, excluding heparinized saline flush; Suspected embolic stroke due to infection or infectious endocarditis; Severe allergy to contrast agents or tirofiban.
Immediate intra-arterial tirofiban (0.5 mg) infusion administered after achieving eTICI 2c-3 complete recanalization in patients with acute ischemic stroke due to large-vessel occlusion. The infusion is delivered over 10 minutes (1 mL/min).
Time frame: 90±7 Days
The primary outcome of this study is the proportion of participants with a modified Rankin Scale (mRS) score of 0-1 at 90±7 days, indicating functional independence after treatment with intra-arterial tirofiban following mechanical thrombectomy for acute ischemic stroke due to large-vessel occlusion
Time frame: 90±7 days
The secondary outcome of this study is the proportion of participants with a modified Rankin Scale (mRS) score of 0-2 at 90±7 days, indicating mild disability after treatment with intra-arterial tirofiban following mechanical thrombectomy for acute ischemic stroke due to large-vessel occlusion.
Time frame: 90±7 Days
This secondary outcome measures the proportion of participants with a modified Rankin Scale (mRS) score of 0-3 at 90±7 days, indicating moderate disability
Time frame: 48 hours
This secondary outcome evaluates the incidence of symptomatic intracranial hemorrhage (sICH) within 48 hours after treatment.
Time frame: 48 hours
This outcome measures the occurrence of any intracranial hemorrhage (ICH) within 48 hours following the intervention
Time frame: 90±7 days
This secondary outcome evaluates the all-cause mortality rate at 90±7 days.
Time frame: 48 hours
Early neurological improvement is defined as a decrease of 10 or more points from baseline in the National Institutes of Health Stroke Scale (NIHSS) score at 48 hours after treatment. The NIHSS ranges from 0 to 42, with higher scores indicating more severe neurological impairment and a worse outcome.
Time frame: 90±7 days
Health-related quality of life will be measured at 90±7 days using the European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Scores range from -0.39 to 1, with higher scores indicating better quality of life.
Contact information is provided by the study sponsor or research team.
Shandong Provincial Hospital
Other Gov
Efficacy and Safety of Immediate Intra-Arterial Tirofiban After Mechanical Thrombectomy Recanalization in Acute Intracranial Large-Vessel Occlusion
Acronym: IA-Tirofiban
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06788626
Acute Ischemic Stroke, Brain Diseases
Hefei, Anhui, China
View Trial DetailsNCT06179017
Acute Ischemic Stroke, Brain Diseases
Fuzhou, Fujian, China
View Trial DetailsNCT05847309
Acute Ischemic Stroke, Brain Diseases
Santiago de Compostela, A Coruña, Spain
View Trial DetailsNCT05631847
Acute Ischemic Stroke, Alteplase
Chongqing, Chongqing Municipality, China
View Trial Details